logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Kei Muro

Department of Clinical Oncology
H指数:80
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G

晚期胃癌伴严重腹膜转移患者mFOLFOX6方案的II期研究（WJOG10517G），包括与JCOG1108/WJOG7312G的个体患者数据比较

Gastric Cancer
IF5.1
2026-08-270
OAAI
Toshiki Masuishi; Hiroki Hara; Takayuki Ando; Takeshi Kawakami; Yoshiyuki Yamamoto; Naotoshi Sugimoto; Kazuhiro Shiraishi; Taito Esaki; Yuji Negoro; Takao Tsuzuki; Hiroaki Sawai; Masato Nakamura; Takashi Inagaki; Yudai Shinohara; Kentaro Kawakami; Seiichiro Mitani; Kenji Tsuchihashi; Chihiro Kondoh; Hiroo Katsuya; Osamu Maeda; Yuriko Fujita; Kenichi Yoshimura; Masanori Terashima; Takako Eguchi Nakajima; Kei Muro
Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study

开发用于估算日本系统性癌症治疗自付费用及基于理赔数据的协议评估的可视化工具：VEST-Ca研究

Japanese Journal of Clinical Oncology
IF2.2
2026-08-010
PRE
Honda, Kazunori; Shimomura, Kazuhiro; Taniguchi, Hiroya; Kadowaki, Shigenori; Masuishi, Toshiki; Narita, Yukiya; Mizuno, Taro; Ando, Taiju; Ishizuka, Yasunobu; Umegaki, Sho; Ando, Masashi; Muro, Kei
Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer

C-SOLVE (JACCRO GC-12)临床试验研究方案；一项关于CapeOX或SOX联合佐尔帕妥单抗治疗HER2阴性、CLDN18.2阳性不可切除的晚期胃或胃食管结合部癌的随机、非对照II期临床试验

BMC Cancer
IF3.4
2026-07-170
OA
Satoshi Yuki; Hisato Kawakami; Kazuaki Harada; Yohei Kubota; Kyongsun Pak; Yoshihiro Kakeji; Masanori Terashima; Eishi Baba; Kei Muro; Yu Sunakawa; Wataru Ichikawa; Masashi Fujii
Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

含Ramucirumab的化疗方案用于对铂类为基础的化疗方案耐药/不耐受的胃肠道神经内分泌癌患者的疗效：一项多中心观察性回顾研究（WJOG13420G）

International Journal of Cancer
IF4.7
2025-07-230
OAAI
Yuki Matsubara; Toshiki Masuishi; Waki Hosoda; Hidekazu Hirano; Saori Mishima; Hiroyuki Takahashi; Tomoyuki Otsuka; Kenta Kawasaki; Takeshi Kawakami; Kazuhiro Yanagihara; Takaya Shimura; Masato Komoda; Kozue Murayama; Keiko Minashi; Yoshiyuki Yamamoto; Yudai Shinohara; Shinichi Nishina; Nobuyuki Musha; Kyoko Kato; Kentaro Kawakami; Katsunori Shinozaki; Kenji Tsuchihashi; Takayuki Ando; Yosuke Kito; Akitaka Makiyama; Seiichiro Mitani; Kaori Hino; Naoki Izawa; Isao Oze; Kei Muro
Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study

恩沃利单抗（enfortumab vedotin）在铂类和PD-1/PD-L1抑制剂方案治疗后疾病进展的晚期非小细胞肺癌患者中的疗效：国际多中心EV-202期2研究

European Journal of Cancer
IF7.1
2025-07-090
OA
Kei Muro; Trevor Feinstein; Joaquina Baranda; Ioana Bonta; Noriko Yanagitani; Todd Gersten; Leena Gandhi; Toshihiro Kudo; Naomi Fujioka; Jason Kaplan; Seema Gorla; Shubin Liu; Michele Wozniak; Srinivasu Poondru; Ryan Dillon; Changting Meng; Tejas Patil
An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

一项关于纳武利尤单抗联合化疗在未经治疗的晚期或复发性胃癌日本真实世界中的有效性与安全性观察研究：G-KNIGHT研究

Gastric Cancer
IF5.1
2025-07-090
OAAI
Shigenori Kadowaki; Tomoyuki Otsuka; Keiko Minashi; Shinichi Nishina; Hiroshi Yabusaki; Chiaki Inagaki; Tomohiro Nishina; Hisateru Yasui; Hiroshi Matsuoka; Nozomu Machida; Masahiro Tsuda; Fumio Nagashima; Hisashi Hosaka; Junichi Matsubara; Hiroyuki Arai; Satoshi Ida; Yuya Kimijima; Yuko Matsuda; Manabu Muto; Kei Muro
Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors

I期研究评估tusamitamab ravtansine单药治疗在日本晚期恶性实体瘤患者中的安全性和药代动力学。

international journal of oncology
IF2.8
2025-05-250
OA
Muro, Kei; Yamazaki, Kentaro; Kadowaki, Shigenori; Mishima, Saori; Kawakami, Takeshi; Tanaka, Tomoyuki; Tada, Keisuke; Fagniez, Nathalie; Ohshima, Shinobu; Yoshino, Takayuki
Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5-Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study

奥沙利铂和5-氟尿嘧啶联合多西他赛新辅助治疗食管癌期间发热性中性粒细胞减少症的最佳一级预防：一项回顾性队列研究

CANCER MEDICINE
IF3.1
2025-04-240
OAAI
Kumanishi, Ryosuke; Taniguchi, Hiroya; Nakazawa, Taiko; Ogata, Takatsugu; Matsubara, Yuki; Kodama, Hiroyuki; Nakata, Akinobu; Honda, Kazunori; Masuishi, Toshiki; Narita, Yukiya; Kadowaki, Shigenori; Ando, Masashi; Tajika, Masahiro; Abe, Tetsuya; Muro, Kei

研究方向

暂未获取到该数据
S
Shigenori Kadowaki
H 指数:36论文数:419被引数:6,979
Y
Yukiya Narita
H 指数:20论文数:198被引数:1,964
K
Kohei Shitara
H 指数:79论文数:1,129被引数:3.5万
T
Toshiki Masuishi
H 指数:24论文数:324被引数:3,035
K
Kentaro Yamazaki
H 指数:46论文数:558被引数:1.4万
T
Takayuki Yoshino
H 指数:88论文数:1,566被引数:5.0万
M
Masahiro Tajika
H 指数:46论文数:362被引数:7,629
N
Narikazu Boku
H 指数:75论文数:815被引数:2.9万
Y
Yoshito Komatsu
H 指数:54论文数:829被引数:1.5万
A
Atsushi Ohtsu
H 指数:90论文数:768被引数:4.2万